DNTH
Dianthus Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$101.00-4.36%
Price as of Jul 20, 2026
DNTH growth
Dianthus Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -79.5%
- EBITDA
- +90.4%
- EBIT
- -63.2%
- EPS
- +96.2%
- Free cash flow
- -43.4%
- Operating cash flow
- -43.4%
Forward estimates
- Revenue
- +56.5%
- EBITDA
- +88.4%
- EPS
- —
Three-year CAGR
- Revenue
- -31.8%
- EBITDA
- -91.5%
- EBIT
- -74.7%
- Net income
- -91.1%
- EPS
- -64.7%
- Free cash flow
- -65.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.